Regulatory ProfessionalsRegulatory ProfessionalsRegulatory ProfessionalsRegulatory Professionals
  • About Us
    • Our Story
    • Leadership
    • Senior Consultants
  • Services
    • Overview
    • Product Development Services
    • Regulatory Consulting Services
    • Electronic Publishing | eCTD
    • Medical and Regulatory Writing
    • Nonclinical Consulting Services
    • CMC Consulting Services
    • Quality Assurance
    • Project Management
    • Electronic Trial Master Files
  • Resources
    • Blog
    • White Papers
    • Webinars
    • News
  • Careers
  • Contact

Speed vs Safety: How Regulators Are Sizing Up Evidence Today

By Linda McBride | Regulatory Affairs, Webinars | Comments are Closed | 2 February, 2021 | 1

In drug development, there is always pressure to move quickly, and with today’s push to develop treatments and vaccines for COVID, those pressures are exacerbated. From sponsors and investors to investigators and regulators, everyone is trying to balance the dual needs for speed and safety.

The places where they find success are likely to change drug development forever.

Adopting decentralized trials and embracing real-world data allows COVID (and other) trials to proceed at a time when typical site visits are fraught. Once global regulators are secure that even under these new circumstances, the data are still valid and clean, these processes are likely to be more widely implemented. In the meantime, sponsors should be confident about working closely with regulators to understand potentially shifting requirements and to build a strong regulatory strategy.

In this webinar, the speakers will ground their predictions for the future in the historic response of regulatory bodies to epidemics, then explore recent shifts in the regulatory environment in response to COVID and the resulting new efficiencies in drug development.

  • How to start the study in the shortest time possible, beginning with an assessment of what country or countries can offer the fastest start-up
  • Strategies for engaging patients, making your study more appealing, safe, and rewarding than competing trials
  • Accelerating the timeline from country selection to first patient screened
  • Evaluating protocol considerations to increase the overall feasibility of the study and optimize regulatory start-up timelines

Presented by:

Linda McBride, Executive Director, Regulatory Affairs and Compliance Regulatory Professionals, a division of Premier Research

Daniel Semere, Senior Regulatory Submissions Manager

No tags.
Avatar

Linda McBride

More posts by Linda McBride

Related Post

  • RPI Acquired by Premier Research to Expand Regulatory Offerings

    By Regulatory Professionals | Comments are Closed

    Read Now

  • In the Spotlight: Recent FDA Updates and Guidance for Rare Disease Drug Development

    By Kristi Miller | Comments are Closed

    Watch Now

  • Regulatory CMC for Biologics / Biopharmaceuticals

    By Regulatory Professionals | Comments are Closed

    Download

  • Streamline Early Clinical Development With an INTERACT Meeting

    By Ann Leonard | Comments are Closed

    Read Now

  • FDA Releases Draft Guidance for Transdermal Product Development

    By Lisa Crose | Comments are Closed

    Read Now

  • UPDATE – Draft FDA Guidance Concerning Combination Products

    By Ann Leonard | Comments are Closed

    Read Now

  • FDA Issues Guidance on Clinical Trials During COVID-19

    By Nach Davé | Comments are Closed

    Read Now

  • Global Health Authorities Push for Rapid Development of COVID-19 Tests, Drugs and Vaccines

    By Katharine Chorlton | Comments are Closed

    Read Now

Recent Posts

  • Product Development Checklist: Considerations for Each Stage of the Drug Development Process
  • Key Changes in the Revised EMA Guidance on Clinical Trials During COVID
  • Advancing Patient Healthcare: Clarifying the 2019 Changes in India’s Drug and Clinical Trial Rules
  • The First Step for Streamlined CMC Development: Optimize the Target Product Profile
  • Speed vs Safety: How Regulators Are Sizing Up Evidence Today

Categories

  • Blog
  • CMC
  • COVID-19
  • FDA
  • INTERACT Meeting
  • News
  • Podcast
  • Regulatory Affairs
  • Webinars
  • White Papers
April 2021
M T W T F S S
« Mar    
 1234
567891011
12131415161718
19202122232425
2627282930  

Headquarters

8000 Jarvis Ave.
Suite 100
Newark, CA 94560

North Carolina

3800 Paramount Parkway
Suite 400
Morrisville, NC 27560-6949

 

San Diego

Aventine Building
8910 University Center Lane
Suite 400 San Diego, CA 92122

United Kingdom

250 South Oak Way
Green Park
Reading, Berkshire, RG2 6UG

Australia

Ground Floor
23 Milton Parade
Malvern VIC 3144

  • About Us
  • Cookie Policy
  • Privacy Notice
  • Contact
Copyright 2021 Regulatory Professionals | All Rights Reserved
  • About Us
    • Our Story
    • Leadership
    • Senior Consultants
  • Services
    • Overview
    • Product Development Services
    • Regulatory Consulting Services
    • Electronic Publishing | eCTD
    • Medical and Regulatory Writing
    • Nonclinical Consulting Services
    • CMC Consulting Services
    • Quality Assurance
    • Project Management
    • Electronic Trial Master Files
  • Resources
    • Blog
    • White Papers
    • Webinars
    • News
  • Careers
  • Contact
Regulatory Professionals
XWe use cookies (and equivalent technologies) to collect and analyze information on our Website’s performance and to enable the Website to function. Cookies also allow us and third parties to tailor the ads you see when you visit our Website and other third party websites in the same online network, including social networks. By clicking ‘AGREE', you agree to these uses of cookies. If you do not agree or if you would like more information, you can manage your cookie preferences by clicking on 'Cookie Settings'. Cookie Policy REJECTAGREECookie Settings
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non Necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Save & Accept